UP!

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-03 Future report Set alerts
Q2 2020 2020-08-10 0.00 0.00
Q1 2020 2020-05-07 -0.17 -0.17
Q4 2019 2020-02-25 -0.06 -0.06
Q3 2019 2019-11-05 -1.26 -1.26
Q2 2019 2019-08-08 -0.35 -0.35
Q1 2019 2019-05-09 -0.35 -0.35
Q4 2018 2019-03-05 -0.29 -0.29
Q3 2018 2018-11-08 -0.33 -0.33
Q2 2018 2018-08-08 -0.39 -0.39

Ratings

2016-05-10 Reiterated Rating FBR & Co. Hold
2016-05-10 Reiterated Rating FBR & Co Hold
2016-03-01 Reiterated Rating Citigroup Inc. Hold
2016-02-29 Reiterated Rating Piper Jaffray Buy
2016-02-29 Reiterated Rating Piper Jaffray Cos. Buy
2016-02-23 Lower Price Target William Blair Market Perform $12.00 to $8.00
2016-02-23 Lower Price Target FBR & Co. Market Perform $14.00 to $10.00
2016-02-23 Downgrade Barclays Overweight to Equal Weight $12.00 to $6.00
2016-02-23 Downgrade Barclays PLC Overweight to Equal Weight $12.00 to $6.00
2016-02-22 Reiterated Rating Piper Jaffray Overweight $18.00
2016-02-22 Downgrade Citigroup Inc. Buy to Neutral $13.00 to $9.00
2016-02-22 Downgrade Morgan Stanley Equal Weight to Underweight $8.00 to $5.00
2016-02-19 Lower Price Target Citigroup Inc. $19.00 to $13.00
2016-02-10 Reiterated Rating FBR & Co. Market Perform
2016-02-06 Reiterated Rating Citigroup Inc. Buy
2016-01-19 Reiterated Rating Piper Jaffray Overweight $11.00 to $18.00
2016-01-12 Reiterated Rating FBR & Co. Market Perform $14.00
2016-01-04 Downgrade William Blair Hold
2016-01-04 Downgrade JPMorgan Chase & Co. Hold
2016-01-04 Reiterated Rating Morgan Stanley Hold
2016-01-03 Reiterated Rating Piper Jaffray Buy $10.00 to $11.00
2016-01-03 Downgrade Brean Capital Hold
2016-01-03 Downgrade Cowen and Company Hold
2016-01-03 Reiterated Rating Citigroup Inc. Buy
2016-01-03 Downgrade Stifel Nicolaus Hold
2015-12-30 Reiterated Rating Empire Equal Weight
2015-12-30 Reiterated Rating Barclays Buy
2015-12-30 Lower Price Target Janney Montgomery Scott Neutral $14.00
2015-12-29 Reiterated Rating Morgan Stanley Hold $50.00 to $8.00
2015-12-29 Downgrade William Blair Outperform to Market Perform $62.00 to $12.00
2015-12-29 Downgrade JPMorgan Chase & Co. Overweight to Neutral $65.00 to $15.00
2015-12-29 Lower Price Target Barclays Overweight $65.00 to $12.00
2015-12-28 Reiterated Rating Citigroup Inc. Buy $80.00 to $19.00
2015-12-28 Downgrade Cowen and Company Outperform to Market Perform $65.00 to $8.00
2015-12-28 Downgrade Brean Capital Buy to Hold
2015-12-28 Reiterated Rating Piper Jaffray Overweight $63.00 to $10.00
2015-12-28 Downgrade FBR & Co. Outperform to Market Perform $73.00 to $14.00
2015-12-28 Downgrade Stifel Nicolaus Buy to Hold
2015-12-01 Initiated Coverage Janney Montgomery Scott Neutral $50.00
2015-12-01 Reiterated Rating Piper Jaffray Buy
2015-11-05 Reiterated Rating Brean Capital Buy $57.00
2015-10-27 Reiterated Rating William Blair Buy $62.00
2015-10-23 Reiterated Rating Piper Jaffray Overweight $63.00
2015-10-23 Reiterated Rating Cowen and Company Outperform $65.00
2015-10-11 Reiterated Rating William Blair Outperform $62.00
2015-10-05 Downgrade Morgan Stanley Overweight to Equal Weight $56.00 to $50.00
2015-09-10 Reiterated Rating William Blair Buy
2015-09-08 Reiterated Rating Cantor Fitzgerald Buy $57.00
2015-09-03 Initiated Coverage Citigroup Inc. Buy
2015-08-18 Initiated Coverage FBR & Co. Outperform $73.00
2015-08-10 Reiterated Rating Cantor Fitzgerald Buy $57.00
2015-08-06 Boost Price Target Brean Capital Buy $50.00 to $57.00
2015-08-04 Reiterated Rating Piper Jaffray Overweight $44.00 to $63.00
2015-07-23 Reiterated Rating Piper Jaffray Buy $44.00
2015-05-23 Reiterated Rating William Blair Outperform $57.00
2015-05-12 Reiterated Rating William Blair Outperform $57.00
2015-05-11 Set Price Target Piper Jaffray Buy $44.00
2015-05-11 Boost Price Target Brean Capital Buy $45.00 to $50.00
2015-04-15 Reiterated Rating Brean Capital Buy $45.00
2015-04-14 Set Price Target Piper Jaffray Buy $44.00
2015-03-09 Reiterated Rating Cantor Fitzgerald Buy $39.00 to $57.00
2015-03-06 Set Price Target Piper Jaffray Buy $44.00
2015-03-06 Set Price Target Brean Capital Buy $45.00
2015-03-03 Initiated Coverage Barclays Overweight $55.00
2015-02-12 Boost Price Target Stifel Nicolaus Buy $47.00 to $57.00
2015-02-03 Initiated Coverage JPMorgan Chase & Co. Overweight $51.00
2014-12-31 Boost Price Target Brean Capital Buy $33.00 to $45.00
2014-10-16 Boost Price Target Cantor Fitzgerald Buy $33.00 to $39.00
2014-10-02 Reiterated Rating Piper Jaffray Overweight $33.00 to $37.00
2014-09-08 Initiated Coverage Cantor Fitzgerald Buy $33.00
2014-08-25 Lower Price Target Morgan Stanley $34.00 to $33.00
2014-07-08 Initiated Coverage Brean Capital Buy $33.00
2014-06-23 Initiated Coverage Brean Capital Buy $33.00
2014-03-13 Initiated Coverage Stifel Nicolaus Buy $34.00
2014-03-12 Reiterated Rating Morgan Stanley Overweight $34.00
2014-02-13 Initiated Coverage Canaccord Genuity Buy
2013-11-26 Initiated Coverage Piper Jaffray Overweight $33.00
2016-05-10 Reiterated Rating FBR & Co. Hold
2016-05-10 Reiterated Rating FBR & Co Hold
2016-03-01 Reiterated Rating Citigroup Inc. Hold
2016-02-29 Reiterated Rating Piper Jaffray Buy
2016-02-29 Reiterated Rating Piper Jaffray Cos. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In CMRX 0 funds of 2184 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
Sanderling Venture Partners V, LP 9.28%  (3311400) CMRX /
Hutton Wende S 7.25%  (2584990) CMRX / DERM /
ALTA BIOPHARMA PARTNERS III LP Stockholder 6.06%  (2161829) AEGR / CARA / CMRX / MGNX / SNSS /
CHAMPSI FARAH 4.81%  (1714330) CMRX / KITE / PTLA / TRVN /
New Leaf Ventures II, L.P. 4.33%  (1543394) CMRX / DRTX / MEIP / VSAR /
A.M. Pappas Life Science Ventures IV LP Stockholder 2.94%  (1047535) CMRX /
NIEDEL JAMES 2.93%  (1046082) CMRX /
PAPPAS ARTHUR M 2.33%  (830695) CMRX /
Sanderling Venture Partners VI Co Investment Fund LP 1.96%  (697346) CMRX /
Berrey M Michelle Chief Medical Officer 0.87%  (311336) CMRX /
MARIO ERNEST 0.81%  (288826) BSX / CAPN / CELG / CMRX / KIN / TNXP / VVUS / XNPT /
Trost Timothy W. Sr. Vice President and CFO 0.31%  (111931) CMRX /
Nichols Garrett Chief Medical Officer 0.27%  (96151) CMRX /
Richardson Linda M Chief Commercial Officer 0.16%  (58706) CMRX /
Rogers Michael D. Chief Development Officer 0.06%  (21630) CMRX /
DEMSKI MARTHA J 0.03%  (10000) ADMS / CMRX / NEOT /
Machado Clarence Patrick 0.03%  (10000) AAVL / CMRX / ECYT / MDVN / SCYX / TKMR /
WOLLAEGER TIMOTHY 0.02%  (8702) CMRX /
DRAKE RODMAN L 0.01%  (3500) CELG / CMRX /
Ricciardi Lisa 0.01%  (1950) CFRX / CMRX /

Comments